Levetiracetam Strides

Levetiracetam, the active ingredient in Levetiracetam Strides, is an anticonvulsant presented as an oral tablet for oral use. It is employed to control partial, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy. The medication is indicated for both adult and pediatric populations, subject to physician assessment.

GNH USA supplies Levetiracetam Strides as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across EU and global markets. We also provide comprehensive documentation and support for import licensing.

Levetiracetam is an antiepileptic drug that modulates synaptic vesicle protein SV2A to reduce neuronal excitability in various seizure disorders.

Partial seizures: lowers seizure frequency and severity in patients with focal onset epilepsy. Generalized tonic‑clonic seizures: helps prevent convulsive episodes and reduces the risk of injury in individuals with generalized seizures. Myoclonic seizures: decreases the occurrence of sudden muscle jerks, improving daily function for patients with myoclonic epilepsy. Adjunct therapy: can be combined with other antiepileptic agents to achieve optimal seizure control in refractory cases.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired or low in energy. - Somnolence: increased sleepiness, especially after dosing. - Headache: mild to moderate head pain. - Irritability: mood changes or increased agitation.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions requiring immediate medical attention. - Suicidal thoughts or severe depression: monitor mental health closely. - Blood dyscrasias: rare cases of leukopenia or thrombocytopenia. - Multi‑organ hypersensitivity: systemic allergic response affecting multiple organ systems.

When prescribing Levetiracetam Strides, clinicians should consider several safety aspects.

Pregnancy: Category B – use only if the potential benefit justifies the potential risk to the fetus. Renal impairment: dose adjustment may be required based on renal clearance. Mood changes: monitor patients for depression, anxiety, or suicidal ideation. Driving: dizziness or somnolence may impair ability to operate machinery; advise caution. Drug interactions: review concomitant medications for potential pharmacodynamic or pharmacokinetic effects. Store at room temperature: keep in the original container, protect from moisture and heat.

Levetiracetam can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Alcohol: may increase central nervous system depression. - Carbamazepine: enzyme induction can lower levetiracetam plasma concentrations. - Phenobarbital: may reduce levetiracetam efficacy through increased metabolism.

Moderate Interactions (Monitor Closely): - Valproic acid: may raise levetiracetam levels, requiring monitoring. - Oral contraceptives: levetiracetam may reduce hormonal contraceptive effectiveness. - Other antiepileptic drugs (e.g., phenytoin): may alter levetiracetam plasma concentrations, necessitating dosage review.